Advances in Custom Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advances in Custom Synthesis
As contract manufacturers and drug companies meet at Informex, the stage is set for the latest in pharmaceutical chemical development.


Pharmaceutical Technology
Volume 34, Issue 2, pp. 46-51

References

1. B. Wu, J.R. Parquette, T.V. RajanBabu, Science 362 (5960), 1662 (2009).

2. C. Kanta De, E.G. Klauber, and D. Seidel, J. Amer. Chem. Soc. 131 (47), 17060–17061 (2009).

3. C. Drahl, Chem. Engin. News 88 (2), 5 (2010).

4. I.B. Seiple et al. Agnew. Chem. Intel. Ed. Engl., DOI://10:1002/anie.200907112 (2010).

5. J. Quan Yu et al., Science 327 (5963), 315–319 (2010).

6. I. Andrews et al., Org. Process Res. Dev. 14 (1), 19–29 (2010).

7. P. Van Arnum, "Deploying Green Chemistry in API Synthesis," Pharm. Technol. Sourcing and Management, July 8, 2009, http://PharmTech.com/ptsm.

8. EPA, Green Chemistry Challenge Agency Awards Program: Summary of 2009 Award Entries and Recipients (Washington, DC, 2009).

9. B.H. Lipshutz et al., Org. Lett. 10 (7), 1325–1328 (2008).

10. B.H. Lipshutz et al., Org. Lett. 10 (7), 1329–1332 (2008).

11. B.H. Lipshutz et al., Org. Lett. 10 (7), 1333–1336 (2008).

12. L.R. MacGillivray, J. Org. Chem. 73 (9), 3311–3317 (2008).

13. L.R. MacGillivray et al., Acc. Chem. Res. 41 (2), 280–291 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here